Terns Pharmaceuticals (TERN) Stock Forecast, Price Target & Predictions
TERN Stock Forecast
Terns Pharmaceuticals stock forecast is as follows: an average price target of $12.50 (represents a 39.51% upside from TERN’s last price of $8.96) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
TERN Price Target
The average price target for Terns Pharmaceuticals (TERN) is $12.50 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $19.00 to $7.00. This represents a potential 39.51% upside from TERN's last price of $8.96.
TERN Analyst Ratings
According to 8 Wall Street analysts, Terns Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for TERN stock is 0 'Strong Buy' (0.00%), 6 'Buy' (75.00%), 2 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Terns Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 21, 2024 | Graig Suvannavejh | Mizuho Securities | $10.00 | $7.79 | 28.37% | 11.61% |
| Mar 15, 2024 | Etzer Darout | BMO Capital | $19.00 | $7.20 | 163.89% | 112.05% |
| Dec 29, 2022 | - | H.C. Wainwright | $7.00 | $9.60 | -27.08% | -21.88% |
| Dec 20, 2022 | - | Goldman Sachs | $14.00 | $7.78 | 79.95% | 56.25% |
| Sep 27, 2022 | Corinne Jenkins | Goldman Sachs | $9.00 | $4.92 | 82.93% | 0.45% |
The latest Terns Pharmaceuticals stock forecast, released on Aug 21, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $10.00, which represents a 28.37% increase from the stock price at the time of the forecast ($7.79), and a 11.61% increase from TERN last price ($8.96).
Terns Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 2 |
| Avg Price Target | $10.00 | $10.00 | $14.50 |
| Last Closing Price | $8.96 | $8.96 | $8.96 |
| Upside/Downside | 11.61% | 11.61% | 61.83% |
In the current month, the average price target of Terns Pharmaceuticals stock is $10.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 11.61% increase as opposed to Terns Pharmaceuticals's last price of $8.96. This month's average price target is down 0.00% compared to last quarter, and down -31.03% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 10, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Sep 10, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Sep 10, 2024 | Deutsche Bank | - | Buy | Upgrade |
| Sep 10, 2024 | Loop Capital Markets | Buy | Buy | Hold |
| Sep 10, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Aug 10, 2023 | Needham | Neutral | Neutral | Hold |
| Jun 28, 2023 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Feb 07, 2023 | UBS | - | Buy | Initialise |
| Dec 29, 2022 | Citigroup | Neutral | Neutral | Hold |
| Dec 20, 2022 | Goldman Sachs | Buy | Buy | Hold |
Terns Pharmaceuticals's last stock rating was published by JMP Securities on Sep 10, 2024. The company gave TERN a "Market Outperform" rating, the same as its previous rate.
Terns Pharmaceuticals Financial Forecast
Terns Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $2.92M | - | - |
| High Forecast | - | - | - | - | $2.92M | - | - |
| Low Forecast | - | - | - | - | $2.92M | - | - |
| # Analysts | 4 | 4 | 4 | 4 | 6 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - |
Terns Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. TERN's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Terns Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 6 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $1.75M | - | - |
| High Forecast | - | - | - | - | $1.75M | - | - |
| Low Forecast | - | - | - | - | $1.75M | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict TERN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Terns Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Terns Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 6 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-25.75M | $-25.67M | $-26.05M | $-25.92M | $-24.82M | $-25.05M | $-25.25M |
| High Forecast | $-25.75M | $-25.67M | $-26.05M | $-25.92M | $-24.82M | $-22.77M | $-25.25M |
| Low Forecast | $-25.75M | $-25.67M | $-26.05M | $-25.92M | $-24.82M | $-28.09M | $-25.25M |
| Surprise % | - | - | - | - | - | - | - |
Terns Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TERN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Terns Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 6 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $13.78M | - | - |
| High Forecast | - | - | - | - | $13.78M | - | - |
| Low Forecast | - | - | - | - | $13.78M | - | - |
| Surprise % | - | - | - | - | - | - | - |
Terns Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to TERN last annual SG&A of $NaN (undefined).
Terns Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 6 | 3 | 3 |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.35 | $-0.34 | $-0.35 | $-0.35 | $-0.33 | $-0.34 | $-0.34 |
| High Forecast | $-0.35 | $-0.34 | $-0.35 | $-0.35 | $-0.33 | $-0.31 | $-0.34 |
| Low Forecast | $-0.35 | $-0.34 | $-0.35 | $-0.35 | $-0.33 | $-0.38 | $-0.34 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Terns Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TERN previous annual EPS of $NaN (undefined).
Terns Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
TERN Forecast FAQ
Is Terns Pharmaceuticals a good buy?
Yes, according to 8 Wall Street analysts, Terns Pharmaceuticals (TERN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 75.00% of TERN's total ratings.
What is TERN's price target?
Terns Pharmaceuticals (TERN) average price target is $12.5 with a range of $7 to $19, implying a 39.51% from its last price of $8.96. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Terns Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for TERN stock, the company can go up by 39.51% (from the last price of $8.96 to the average price target of $12.5), up by 112.05% based on the highest stock price target, and down by -21.88% based on the lowest stock price target.
Can Terns Pharmaceuticals stock reach $13?
TERN's highest twelve months analyst stock price target of $19 supports the claim that Terns Pharmaceuticals can reach $13 in the near future.
What is Terns Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $10 price target for Terns Pharmaceuticals (TERN) this month, up 11.61% from its last price of $8.96. Compared to the last 3 and 12 months, the average price target increased by 11.61% and increased by 61.83%, respectively.
What are Terns Pharmaceuticals's analysts' financial forecasts?
Terns Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.92M (high $2.92M, low $2.92M), average EBITDA is $1.76M (high $1.76M, low $1.76M), average net income is $-75.115M (high $-72.838M, low $-78.151M), average SG&A $13.78M (high $13.78M, low $13.78M), and average EPS is $-1.009 (high $-0.978, low $-1.05). TERN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-103M (high $-103M, low $-103M), average SG&A $0 (high $0, low $0), and average EPS is $-1.389 (high $-1.389, low $-1.389).